We are now conducting research to evaluate the safety, tolerability and preliminary overall response rate (including the complete response and partial response rate) of auranofin treatment in patients with relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, or prolymphocytic lymphoma based on criteria for patients in clinical practice. This is an investigator-initiated trial led by Kapil Bhalla, MD.
Patients must have histologically confirmed B-cell CLL, SLL, PLL arising from CLL/SLL or Richter’s transformation according to WHO criteria and require therapy based on the 2008 revised IWCLL criteria.
Get more information on this clinical trial.
Medical research finds ways to help people live longer, improve their quality of life and manage or cure disease. This is possible because of the people who volunteer to participate in clinical trials.